Report Overview

The EU Melanoma Therapeutics market was valued at USD 750 million in 2019 and is expected to reach USD XX million by 2028 at a CAGR of XX% during the forecast period

Melanoma is a type of skin cancer that develops in the melanocyte cells that are responsible for producing melanin, the pigment that imparts color to the skin. It occurs when unrepaired damage to skin cells leads to their rapid multiplication, thus forming malignant tumors. The primary cause of Melanoma is prolonged exposure to ultraviolet light. If detected and treated at an early stage, the disease is almost always curable. EU shows a higher market expansion because of the treatment rates and the market infiltration of premium drugs. The market for melanoma drug therapeutics is increasing at a significant rate due to an increase in the prevalence of melanoma and improvement in healthcare facilities



Market Growth Drivers

The entry of biosimilars into the market is expected to increase during the forecast period due to the patent expiration of key branded biologics. Effective immunotherapies and technological advancements in melanoma therapeutics would fuel the market further. The government initiatives in the development of novel therapies are anticipated to increase the demand, hence drive the market. The prevalence of skin allergies, melanoma, and other skin cancers in the EU is high, which serves as an opportunity for drug companies to gain a larger share in these regions. Also, the lack of awareness and high cost are expected to act as a restrain in driving the market growth during the forecast period